PDF(Pubmed)
Abstract：
BRAF V600E mutation-positive advanced recurrent colorectal cancer has a poor prognosis. Encorafenib, binimetinib, and cetuximab were approved for use to treat this cancer in 2020 in Japan. Here, we present the case of a patient with BRAF V600E mutation-positive colorectal cancer, who was treated with encorafenib, binimetinib, and cetuximab, and developed grade 3 pancreatitis at our hospital. After pancreatitis treatment, the drug doses were reduced from 300 mg to 225 mg of encorafenib and from 90 mg to 60 mg of binimetinib, and the treatment was resumed. Since then, no grade 3 or higher adverse events were observed. Although pancreatitis has been reported to occur after the use of encorafenib and binimetinib, it is rare. With appropriate dose reduction and attention to side effects, this regimen is considered feasible for the long-term treatment of BRAF V600E mutation-positive advanced recurrent colorectal cancer in patients aged >70 years.
摘要：
BRAFV600E突变阳性晚期复发性结直肠癌预后不良.恩科拉非尼,比米替尼,西妥昔单抗于2020年在日本被批准用于治疗这种癌症。这里,我们介绍了一例BRAFV600E突变阳性结直肠癌患者，接受恩科拉非尼治疗的人,比米替尼,和西妥昔单抗,并在我们医院发展为3级胰腺炎。胰腺炎治疗后，药物剂量从300mg减少到225mg的恩科拉非尼，从90mg减少到60mg的比米替尼，并恢复治疗。从那以后,没有观察到3级或更高的不良事件.尽管据报道在使用恩科拉非尼和比米替尼后会发生胰腺炎，这是罕见的。适当减少剂量并注意副作用，对于年龄>70岁的BRAFV600E突变阳性晚期复发性结直肠癌患者,该方案被认为是长期治疗可行的.
